CA-102N is under clinical development by Holy Stone Healthcare and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect CA-102N’s likelihood of approval (LoA) and phase transition for Metastatic Colorectal Cancer took place on 09 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 09 Nov 2022 increased CA-102N’s Phase Transition Success Rate (PTSR) for Solid Tumor.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CA-102N Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
CA-102N is under development for the treatment of solid tumors including colorectal cancer. It is a carrier-mediated drug delivery product where hyaluronic acid is conjugated to Nimuselide-NH2.It is administered as an intravenous infusion solution. It is developed as Hyaluronic Acid Conjugated Drug (HACD). It acts by targeting CD44.
Holy Stone Healthcare overview
Holy Stone Healthcare is a Taiwan-based company principally engaged in the manufacture and wholesale of medical equipment. The Company’s main products include latent tuberculosis infection test reagents, Ostenil branded joint cavity injection and o
Quick View CA-102N LOA Data
|Highest Development Stage|